Top 50 Biotech VC Funds in United States

A list of 50 United States vc funds investing in biotech. Updated every month. Powered by Shizune.
Investors in the list rank based on the number of investments in Biotech United states companies. The investor list contains vc funds. You can find favourite industries and stages of each investor on the list.
Biotech VC Funds in United States
Name Number of investments Relevant deals Favorite stages Favorite industries Description In
ARCH Venture Partners 274 85 Series A; Series B; Series C Science/Engineering; Biotechnology; Health Care ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Alexandria Venture Investments 161 67 Series A; Series B; Series C Science/Engineering; Biotechnology; Health Care Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
New Enterprise Associates 1148 59 Series B; Series A; Series C Software; Science/Engineering; Health Care New Enterprise Associates, Inc. is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’slifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.
OrbiMed 349 56 Series B; Series A; Series C Health Care; Science/Engineering; Biotechnology Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
MPM Capital 186 56 Series A; Series B; Series C Health Care; Science/Engineering; Biotechnology Powering Breakthroughs in Life Sciences
Versant Ventures 229 55 Series A; Series B; Series C Health Care; Science/Engineering; Biotechnology Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Atlas Venture 309 55 Series A; Series B; Series C Science/Engineering; Health Care; Biotechnology Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on the most compelling opportunities to build scalable businesses and realize value.
Third Rock Ventures 116 53 Series A; Series B; Series C Health Care; Biotechnology; Science/Engineering Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
5AM Ventures 136 53 Series A; Series B; Series C Science/Engineering; Biotechnology; Health Care 5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
BioAdvance 111 47 Seed; Funding Round; Series A Health Care; Science/Engineering; Biotechnology BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Polaris Partners 328 47 Series B; Series A; Series C Health Care; Science/Engineering; Biotechnology Polaris Partners ​has over 20-year history partnering with ​repeat entrepreneurs and innovators who are improving the way people live and work. The ​multibillion-dollar firm invests in healthcare and technology companies ​across all stages, from founding to profitable growth. ​Polaris has offices in Boston and San Francisco. ​Polaris Partners wasfounded in 1996 and is headquartered in Boston, Massachusetts.
F-Prime Capital 250 42 Series A; Series B; Series C Health Care; Science/Engineering; Biotechnology We create and invest in healthcare and technology companies that improve lives all over the world.
Khosla Ventures 639 41 Series A; Series B; Seed Software; Science/Engineering; Health Care Khosla Ventures is a venture capital firm started in 2004 by Vinod Khosla, Co-Founder of Sun Microsystems. The firm provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies.With over $15b assets under management, the firm focuses on a range of areas including consumer, enterprise, education,advertising, financial services, semiconductors, health, big data, agriculture, food, sustainable energy, and robotics. Khosla Ventures is headquartered in Menlo Park, California.
Frazier Healthcare Partners 153 39 Series A; Series B; Post-IPO Equity Health Care; Science/Engineering; Biotechnology Frazier Healthcare Partners: Investing exclusively in healthcare for 25 years.
Fifty Years 124 37 Seed; Series A; Series B Science/Engineering; Health Care; Biotechnology WE BACK HEROES using technology to solve the world's biggest problems
Connecticut Innovations 192 37 Series A; Seed; Funding Round Health Care; Science/Engineering; Software At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Canaan Partners 459 36 Series A; Series B; Series C Software; Science/Engineering; Health Care Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
The Column Group 100 36 Series A; Series B; Series C Biotechnology; Science/Engineering; Health Care The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Hatteras Venture Partners 100 36 Series A; Series B; Funding Round Health Care; Science/Engineering; Biotechnology Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
RA Capital Management 221 36 Series B; Series A; Series C Science/Engineering; Health Care; Biotechnology RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. Their team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. Theyinvest in companies with promising technologies and products. Their approach is to achieve a superior understanding of data, experimental/trial design, regulatory process, and commercial potential. When appropriate, they can offer their portfolio companies leads on in-licensing opportunities and strategic partnerships, as well as insight into the demands of the public markets.
Novartis Venture Fund 170 35 Series B; Series A; Series C Health Care; Science/Engineering; Biotechnology Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific
Boston Harbor Angels 103 34 Angel; Seed; Series A Health Care; Science/Engineering; Biotechnology Boston Harbor Angels is a group of proven business leaders interested in investing a portion of their assets in high growth, early stage companies. The group was formed in February 2004 and since then has made a number of investments in companies in medical devices, IT, consumer products, business products, specialty materials, Internet, aviation,etc. They believe they contribute more than money to the companies they fund and welcome the opportunity to work with entrepreneurs open to take advice, yet having the smarts and determination to make the company successful.Their focus is on early stage companies usually looking to raise $250K to $1.5M, where they can fund a portion of the round and syndicate the deal with other angel groups or early stage venture funds. The stage of the company should be close to commercialization, while the company should have a clear and defensible competitive advantage. They are looking for capital efficient businesses, which can reach profitability with less than $5M of equity investment and provide at least 10X return on the investment within 5 years.They do not invest as a fund - each of their members makes his or her individual investment decision but they collaborate in Due Diligence. They have a deep expertise in the life sciences field where they usually take the position of a lead investor, but are open to any opportunities that can make a strong business case. In some cases they prefer to be the follow on investor if they cannot identify a person with strong expertise within their group.The group’s strategy is directed by an executive committee which consists of 8 people elected by the group: Wayne Griffith (chairman), Bill McPhee, Henry Kay, Jay Schwartz (membership director), Steve Andress, Peter Miller, Don Freeman and Mic Williams (president and founder). The group’s day-to-day operations are managed by Boris Batchvarov (managing director).They receive 20-30 business summaries each month, out of which they select 8 companies to make a personal presentation to their screening committee. The screening committee consists of volunteers from the group. The presentations are 10 min long followed by 10 min Q&A. 4 of the companies are invited to present to the whole group, with the idea to get the people interested and decide to perform a Due Diligence with the companies before making an investment.
DCVC 270 34 Seed; Series A; Series B Software; Science/Engineering; Data and Analytics Deep Tech VC firm with over $3B under management
Life Science Angels 77 34 Funding Round; Seed; Series A Health Care; Science/Engineering; Biotechnology Life Science Angels, Inc. (LSA) is the premier angel investment group focused solely on healthcare investing, including medical devices, diagnostics, pharmaceuticals, biotechnology, and digital health.
Amgen Ventures 105 34 Series B; Series A; Series C Biotechnology; Science/Engineering; Health Care Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Lux Capital 293 34 Series A; Seed; Series B Software; Science/Engineering; Health Care Lux Capital Management manages of $4 billion in assets focused on founding, seed, early-stage, and growth investments in the physical, material and life sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures our portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Northpond Ventures 96 33 Series A; Series B; Series C Science/Engineering; Biotechnology; Health Care Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Wisconsin Investment Partners 107 31 Funding Round; Seed; Series A Health Care; Science/Engineering; Software Wisconsin Investment Partners is an Angel Investment Group in Madison, Wisconsin founded in 2000 with 20 members.
Andreessen Horowitz 909 30 Series A; Series B; Seed Software; Internet; IT Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, that backs bold entrepreneurs building the future through technology.
KdT Ventures 52 30 Seed; Series A; Series B Science/Engineering; Health Care; Biotechnology KdT Ventures is the standard for early-stage frontier science investing.
Pfizer Venture Investments 118 30 Series B; Series A; Series C Health Care; Biotechnology; Science/Engineering Pfizer Venture Investments is a venture capital firm.
Bay City Capital 103 29 Series B; Series A; Series C Health Care; Biotechnology; Science/Engineering Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition andagribusiness sector fund.
HealthCare Ventures 102 29 Series B; Series A; Series C Science/Engineering; Health Care; Biotechnology HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
Dolby Family Ventures 100 29 Series A; Series B; Seed Science/Engineering; Health Care; Biotechnology Dolby Family Ventures is an early stage venture firm focused on building great technology companies. They partner with best-in-class innovators and strong investment syndicate partners at the seed stage of a company’s development. Unlike many seed investors, They intend to continue to invest across future rounds in our successful portfoliocompanies.
Casdin Capital 157 28 Series B; Series A; Series C Science/Engineering; Biotechnology; Health Care Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Domain Associates 169 28 Series B; Series C; Series A Health Care; Biotechnology; Science/Engineering Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA.Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices,while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics. The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 200 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.
SR One 137 27 Series A; Series B; Series C Health Care; Biotechnology; Science/Engineering SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
St. Louis Arch Angels 73 27 Seed; Series A; Funding Round Health Care; Science/Engineering; Biotechnology The St. Louis Arch Angels is a network of accredited investors who fund early-stage businesses across the St. Louis region.
Sofinnova Investments 164 27 Series B; Series C; Series A Health Care; Science/Engineering; Biotechnology Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Broadview Ventures 63 26 Series A; Seed; Debt Financing Health Care; Science/Engineering; Biotechnology Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.
Partners Innovation Fund 45 26 Series A; Series B; Seed Health Care; Biotechnology; Science/Engineering The Innovation Fund was created in 2007 by Brigham and Women's Hospital and Massachusetts General Hospital to address a growing unmet need for funding emerging technology in the capital gap between invention and product development.The main objective of the fund is to accelerate to market technologies developed by Partners HealthCareinvestigators, thereby enhancing healthcare quality, cost and outcomes. Structured as a separate LLC entity, the $35M Fund is evergreen in design and will reinvest all gains from investments back into the Fund to create capital for additional investments.Investment decision oversight is provided by an independent external committee composed of experts from industry, venture capital and academia.The Fund operates on a venture capital model whereby opportunities are rigorously evaluated on the basis of scientific strength as well as potential for commercial success.The Fund has four major goals:* Capture more value from the PHS research portfolio by creating companies, technologies and solutions that advance and enhance healthcare.* Provide funding for technologies positioned in the capital gap between invention and clinical development.* By demonstrating institutional commitment, attract external capital that will leverage and encourage co-investment.* Generate a return on investment to refresh the fund and provide capital for additional technologies.Gap FundingOver the last five to seven years, the environment for early-stage investing has undergone significant change. As a result of these changes, there is a dearth of funding support for technologies/companies positioned between invention and clinical development. By focusing on this capital gap, the Fund can advance technologies of high commercial potential and medical benefit to a stage where larger, more traditional investment sources are attracted to underwrite the risk.Types of Fund InvestmentsThe Partners Innovation Fund will make two types of investments: Equity and Development.Equity investments are seed and early financings that will catalyze company formation. These investments will often be a Series A stock and co-investors are frequently other early institutional investors, private investors or corporate investment funds.Development investments precede company formation and are intended to validate technologies with a high potential for later commercialization by either new venture formation or out-licensing to an existing market player.For all investments, funds will be reserved for participation in follow-on investments.Innovation Fund ProcessUtilizing a proven venture capital based diligence model, the team conducts in-depth diligence on all opportunities in two steps:1. Initial Screening: Assesses opportunities for high commercial potential. Key project attributes are:* Product concept and value proposition* Intellectual Property Position* Stage of technology development* Market Opportunity* Technology Review* Management Team* Regulatory pathway* Funding requirements* Competitive Analysis* Business Model 2. Evaluation and Investment Decision: During this step, PIF staff conducts extensive diligence to assess the strength of the proposed business in relation to our investment criteria. This process takes place over 3 to 6 months during which time we interact with technical and market experts, possible customers, competitors and potential co-investors as we prepare for presentation of the investment opportunity to our external Investment Committee for final approval.The team will work with investigators and their advisors to develop a project or business plan including connections to potential entrepreneurs, advisors and investors in the venture, private or corporate arena.Venture Launch / Ongoing Support: Once an investment has been approved, the Innovation Fund plays an active role in the ongoing development of the new venture. The team will work on all aspects required to move the new entity forward including recruiting senior management and staff, providing guidance and support in technology development, serving on the Board of Directors and working with management to achieve milestones.
GV 662 26 Series B; Series A; Seed Software; Science/Engineering; Health Care GV provides venture capital funding to bold new companies. Across the fields of life science, enterprise technology, consumer products and services, and frontier technology, GV's portfolio companies aim to improve lives and transform industries. GV's team of world-class engineers, designers, physicians, scientists, marketers, andinvestors work together to provide startups exceptional support.Launched as Google Ventures in 2009, GV is the venture capital arm of Alphabet, Inc. GV helps startups interface with Google, providing unique access to the world’s best technology and talent.GV has $8 billion under management. Notable investment outcomes include Uber, Slack, One Medical Group, Nest, Flatiron Health, and Duo Security. GV is headquartered in Mountain View, California, with offices in San Francisco, Boston, New York, and London.
Takeda Ventures 85 26 Series A; Series B; Funding Round Health Care; Biotechnology; Science/Engineering Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. We are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Innova Memphis 163 26 Seed; Pre-Seed; Series A Health Care; Science/Engineering; Software Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Vivo Capital 141 26 Series B; Series C; Series A Health Care; Science/Engineering; Biotechnology Vivo Capital is a healthcare focused investment firm formed in 1996 that is currently making investments from its $1.4B Vivo Capital Fund IX into promising private healthcare companies and from its $635M Vivo Opportunity Fund into promising public healthcare companies.
Refactor Capital 77 26 Seed; Series A; Series B Health Care; Science/Engineering; Biotechnology Refactor Capital is an early-stage venture capital firm that invests in founders solving fundamental human problems.
Alta Partners 142 26 Series B; Series A; Series C Health Care; Science/Engineering; Biotechnology Alta Partners is a leading healthcare and life sciences venture capital firm, helping entrepreneurs build high-impact companies since 1996.
Omega Funds 109 26 Series A; Series B; Series C Science/Engineering; Health Care; Biotechnology We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
InterWest Partners 270 25 Series B; Series A; Series C Health Care; Science/Engineering; Software InterWest invests an average of about $7 - 15 million over the span of their involvement with each company in their portfolio. They invest in companies through the full range of venture investment stages, and investments may be staged over several rounds of financing. Although they generally begin their involvement in the early stages of acompany's development, they pursue attractive opportunities based on their individual merits rather than their investment stage.
Flagship Pioneering 143 25 Series B; Series C; Series A Science/Engineering; Biotechnology; Health Care We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded
Powered by An algorithm that finds investors. Trusted by 3,000+ startups.